Study of Predictive Factors of Chemoresistance in Ovarian Cancer

Epithelial ovarian cancer (EOC) has a poor prognosis. EOC management requires debulking surgery and chemotherapy based on taxol and carboplatine. Initial response is often good, but most often a recurrence occurred in the first 18 months. Early recurrence signs chemoresistance and palliative treatment. The study of predictive clinical or biological factors is required to adapt therapeutic and develop new treatments.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ovarian Cancer Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Diseases Ovarian Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

LAVOUE

Rennes, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patient > 18 years of age
patient with histological proven epithelial ovarian cancer

Exclusion criteria

patients who can not give their own consent
patients without ovarian cancer

Treatment and study plan

Cancer treatment

Procedure

Chemotherapy and laparoscopic surgery

Other names: Carboplatin, Taxol

Primary outcomes

Chemoresistance defined by clinical recurrence

Time frame: 6 months after the end of chemotherapy
Chemoresistance defined by biological recurrence

Time frame: 6 months after the end of chemotherapy
Chemoresistance defined by radiological recurrence

Time frame: 6 months after the end of chemotherapy

Sponsors and collaborators

Lead sponsor

Rennes University Hospital

Other

Registry information

Acronym: FaCliBioCCo

Important dates

Study start: 2015
Primary completion: 2020
Study completion: 2020
First posted: Aug 25, 2016
Registry last updated: Aug 17, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed